

11	W
Y)	

Ð	IN THE UNITED STATES PA	TENT AND TRADEMARK OFFICE
The the App	olication of:	Group Art Unit: 1653
BROI	OSKY) Examiner: Desai, Anand U.
Serial No.: 1	0/803,541) <u>INFORMATION DISCLOSURE STATEMENT</u>
Filed: March	17, 2004))
Atty. File No.	: 2848-53	CERTIFICATE OF MAILING
DIAGNOSIS	DUCT AND METHODS FOR AND THERAPY FOR ND SKELETAL MUSCLE	I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO THE COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON ALEXANDRIA SHERIDAN ROSS P.C. BY: Tricia E. van Hooser
Mail Stop An Commissione P.O. Box 145 Alexandria, V	r for Patents	
Dear Sir:		
	eferences cited on attached Forr	m PTO-1449 are being called to the attention of the
Examiner.		
⊠	'Copies of the cited non-patent	and/or foreign references are enclosed herewith.
	Copies of the cited U.S. patent	ts and/or patent applications are enclosed herewith.
	Copies of the cited U.S. patent	ts/patent application publications are not enclosed in
		03 and October 19, 2004, whereby patent applications omit copies of U.S. patents and U.S. patent application
	Copies of the cited references a	re not enclosed, in accordance with 37 C.F.R. 1.98(d),
because the re	eferences were cited by or submi	tted to the U.S. Patent and Trademark Office in prior
application Se	erial No filed	, which is relied upon for an earlier
filing date und	der 35 U.S.C. § 120.	
	To the best of applicants' belief	f, the pertinence of the foreign-language references are
believed to be	summarized in the attached Eng	glish abstracts and in the figures, although applicants

do not nece	ssarify vouch for the acc	curacy of the translation.
	Examiner's attention	n is drawn to the following co-pending applications, copies of
which have	been or are being subm	itted:
	Serial No.	filed
	Serial No.	filed
	Other:	

Submission of the above information is not intended as an admission that any item is citable under the statutes or rules to support a rejection, that any item disclosed represents analogous art, or that those skilled in the art would refer to or recognize the pertinence of any reference without the benefit of hindsight, nor should an inference be drawn as to the pertinence of the references based on the order in which they are presented. Submission of this statement should not be taken as an indication that a search has been conducted, or that no better art exists.

It is respectfully requested that the cited information be expressly considered during the prosecution of this application and the references made of record therein.

FEES

37 CFR 1.97(b): No fee is believed due in connection with this submission, because the information disclosure statement submitted herewith is satisfies one of the following conditions ("X" indicates satisfaction):			
Within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d), or			
Within three months of the date of entry into the national stage of an international application as set forth in 37 CFR 1.491 or			
Before the mailing date of a first Office Action on the merits, or			
Before the mailing of a first Office action after the filing of a request for continued examination under 37 CFR 1.114.			
Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970.			
37 CFR 1.97(c): The information disclosure statement transmitted herewith is being filed after all the above conditions (37 CFR 1.97(b)), but before the mailing date of one of the following conditions: (1) a final action under 37 C.F.R. 1.113 or (2) a notice of allowance under 37 C.F.R. 1.311, or (3) an action that otherwise closes prosecution in the application. This Information Disclosure Statement is accompanied by:			
A Certification (below) as specified by 37 C.F.R. 1.97(e). Although no fee is believed due, if any fee is deemed due in connection with this submission, please charge such fee to Deposit Account 19-1970. OR			
Please charge Deposit Account 19-1970 in the amount of \$180.00 for the fee set forth in 37 C.F.R. 1.17(p) for submission of an information disclosure statement. Please credit any overpayment or charge any underpayment to Deposit Account 19-1970.			

	37 CFR 1.97(d): This Information Disclosure Statement is being submitted after the period specified in 37 CFR 1.97(c). This information Disclosure Statement includes a Certification (below) as specified by 37 C.F.R. 1.97(e) AND Applicants hereby requests consideration of the reference(s) disclosed herein. Please charge Deposit Account 19-1970 in the amount of \$180.00 under 37 C.F.R. 1.17(p). Please credit any overpayment or charge any						
	underpayment to Deposit Account 19-1970. Election to pay the fee should not be taken as an indication that applicant(s) cannot execute a certification.						
	Certification (37 C.F.R. 1.97(e)) (Applicable only if checked)						
	The undersigned certifies that:						
	☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(1).						
	☐ A copy of the communication from the foreign patent office is enclosed.						
	OR						
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this statement. 37 C.F.R. 1.97(e)(2).						
	Respectfully submitted,						
	SHERIDAN ROSS P.C.						
Date:dy	By: Angela Dallas Sebor Registration No. 42,460 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141 (303) 863-9700						

_			100			
Cub	stituto for form	1440A/DTO	10.	Comple	te if Known	_
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	(a)	Application Number	10/803541			
IN	FORMAT	TION DISC	LUSURE	Filing Date	March 17, 2004	_
ST	ATEME	NT BY AP	PLICANT 9	First Named Inventor	SOKOL	
•			CRADE ACT	Art Unit	1653	_
				Examiner Name	Desai, Anand U.	
Sheet	1	of	2	Attorney Docket Number	2848-53	_

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-kind Code ^{2 (If known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-	•	·	
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Country		eign Patent Document Number*; Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		PCT	<u> </u>				**************************************	
			ŀ					
			<u> </u>					

		OTHER ART (Including Author, Title, Date, Pertiner	nt Pages, etc.)		
Examiner Initials*	Cite No.1				
	1.	Bergo et al., (2002) Proc Natl Acad Sci U S A 99:13049-54			
	2.	2. Boyartchuk & Rine (1998) Genetics 150:95-101			
	3. Brodsky et al., (2000) Circulation 101:473-6				
	4.	Chaly et al., (1996) J Cell Biochem 62:76-89			
	5. Dalton et al., Cancer Res. 55:3295-3304 (1995)				
6. Fatkin et al., (1999) N Engl J Med 341:1715-24					
	7. Lloyd et al., (2002) Human Molecular Genetics (2002) 11(7):769-777				
8. Lutz et al., (1992) Proc Natl Acad Sci U S A 89:3000-4; Izumi eta l., (2000) Mol Biol Cell 11:4323			(2000) Mol Biol Cell 11:4323-37		
	9.	Marcus et al., (1990) Biochem Biophys Res Commun 172:1310-6			
	10.	Muralikrishna et al., (2001) J Cell Sci 114:4001-11			
	11.	Ostlund et al., (2001) J Cell Sci 114:4435-45			
	12.	Pendas et al., Nat Genet 31:94-99 (2002)	las et al., Nat Genet 31:94-99 (2002)		
	13.	Raharjo et al., (2001) J Cell Sci 114:4447-57			
Examiner Sigature			Date Considered		

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

2

Sheet

AUG 0 8 2005

2

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Complete if Known				
Application Number	10/803541			
Filing Date March 17, 2004				
First Named Inventor	SOKOL			
Art Unit	1653			
Examiner Name	Desai, Anand U.			
Attorney Docket Number	2848-53			

14.	Sinensky et al., J Cell Sci 107:2215-2218 (1994)
 15.	Sullivan et al., (1999) J Cell Biol 147:913-20
16.	Taylor et al., (2003) Journal of the American College of Cardiology, 41:771-780
17.	Trueblood et al., (2000) Molecular and Cellular Biology 20(12):4381-4392

Examiner	Date	
Sigature	Considered	

^{*}EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.